5FU resistance caused by reduced fluoro‑deoxyuridine monophosphate and its reversal using deoxyuridine

Mori,Ryutaro; Futamura,Manabu; Tanahashi,Toshiyuki; Tanaka,Yoshihiro; Matsuhashi,Nobuhisha; Yamaguchi,Kazuya; Yoshida,Kazuhiro

doi:10.3892/ol.2017.6512

5FU resistance caused by reduced fluoro‑deoxyuridine monophosphate and its reversal using deoxyuridine

Authors:
- Ryutaro Mori
- Manabu Futamura
- Toshiyuki Tanahashi
- Yoshihiro Tanaka
- Nobuhisha Matsuhashi
- Kazuya Yamaguchi
- Kazuhiro Yoshida
View Affiliations

Affiliations: Department of Surgical Oncology, Gifu University Graduate School of Medicine, Gifu 501‑1194, Japan
Published online on: June 30, 2017 https://doi.org/10.3892/ol.2017.6512
Pages: 3162-3168

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mechanism of 5‑fluorouracil (5FU) resistance was investigated, focusing on the level of thymidylate synthase (TS) ternary complex formed with fluoro‑deoxyuridine monophosphate (FdUMP). MKN45 and 5FU‑resistant MKN45/F2R cells were treated with 5FU and fluoro‑deoxyuridine (FdU) in combination with deoxyuridine (dU) and thymidine (dT). Subsequently, the levels of ternary complex were determined by western blotting and the cell viability was calculated using an MTT assay. MKN45/F2R cells exhibited 5FU resistance (56.2‑fold relative to MKN45 cells), and demonstrated decreased orotate phosphoribosyltransferase (OPRT) and increased TS levels, requiring a higher concentration of 5FU to induce ternary complex formation than MKN45 cells. Following transfection of small interfering RNA against OPRT, MKN45 exhibited increased resistance to 5FU and decreased ternary complex formation subsequent to treatment with 5FU, indicating that decreased OPRT led to increased 5FU resistance. However, MKN45/F2R also exhibited resistance to FdU, which can be converted to FdUMP without OPRT, and there was decreased ternary complex formation after treatment with FdU, indicating that the 5FU‑resistant cells had the ability to decrease intracellular FdUMP. The addition of dU and thymidine dT to 5FU promoted the formation of ternary complexes and reversed 5FU resistance in MKN45/F2R cells, although dT inhibited the efficacy of raltitrexed (another TS inhibitor). These results suggested that 5FU‑resistant cells had the ability to reduce intracellular FdUMP irrespective of decreased OPRT, which led to resistance to 5FU. This resistance was then inhibited by treatment with dT or dU.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, et al: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
3	Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T and Ohashi Y: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 29:4387–4393. 2011. View Article : Google Scholar : PubMed/NCBI
4	Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, et al: Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): A phase 3 factorial randomised controlled trial. Lancet Oncol. 15:886–893. 2014. View Article : Google Scholar : PubMed/NCBI
5	Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, et al: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
6	Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, Hara T, Chung HC, Satoh T, Cho JY, et al: Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: A randomized study (START). J Cancer Res Clin Oncol. 140:319–328. 2014. View Article : Google Scholar : PubMed/NCBI
7	Kufe DW and Major PP: 5-Fluorouracil incorporation into human breast carcinoma RNA correlates with cytotoxicity. J Biol Chem. 256:9802–9805. 1981.PubMed/NCBI
8	Saito K, Nagashima H, Noguchi K, Yoshisue K, Yokogawa T, Matsushima E, Tahara T and Takagi S: First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers. Cancer Chemother Pharmacol. 73:577–583. 2014. View Article : Google Scholar : PubMed/NCBI
9	Park JG, Collins JM, Gazdar AF, Allegra CJ, Steinberg SM, Greene RF and Kramer BS: Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst. 80:1560–1564. 1988. View Article : Google Scholar : PubMed/NCBI
10	Longley DB, Harkin DP and Johnston PG: 5-fluorouracil: Mechanisms of action and clinical strategies. Nat Rev Cancer. 3:330–338. 2003. View Article : Google Scholar : PubMed/NCBI
11	Goodsell DS: The molecular perspective: Methotrexate. Oncologist. 4:340–341. 1999.PubMed/NCBI
12	Rose MG, Farrell MP and Schmitz JC: Thymidylate synthase: A critical target for cancer chemotherapy. Clin Colorectal Cancer. 1:220–229. 2002. View Article : Google Scholar : PubMed/NCBI
13	Ahmad SI, Kirk SH and Eisenstark A: Thymine metabolism and thymineless death in prokaryotes and eukaryotes. Annu Rev Microbiol. 52:591–625. 1998. View Article : Google Scholar : PubMed/NCBI
14	Peters GJ, Laurensse E, Leyva A, Lankelma J and Pinedo HM: Sensitivity of human, murine and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res. 46:20–28. 1986.PubMed/NCBI
15	Sasako M, Terashima M, Ichikawa W, Ochiai A, Kitada K, Kurahashi I, Sakuramoto S, Katai H, Sano T and Imamura H: Impact of the expression of thymidylate synthase and dihydropyrimidine dehydrogenase genes on survival in stage II/III gastric cancer. Gastric Cancer. 18:538–548. 2015. View Article : Google Scholar : PubMed/NCBI
16	Patel K, Yerram SR, Azad NA and Kern SE: A thymidylate synthase ternary complex-specific antibody, FTS, permits functional monitoring of fluoropyrimidines dosing. Oncotarget. 3:678–685. 2012. View Article : Google Scholar : PubMed/NCBI
17	Tsutani Y, Yoshida K, Sanada Y, Wada Y, Konishi K, Fukushima M and Okada M: Decreased orotate phosphoribosyltransferase activity produces 5-fluorouracil resistance in a human gastric cancer cell line. Oncol Rep. 20:1545–1551. 2008.PubMed/NCBI
18	Drake JC, Allegra CJ and Johnston PG: Immunological quantitation of thymidylate synthase-FdUMP-5,10-methylenetetrahydrofolate ternary complex with the monoclonal antibody TS 106. Anticancer Drugs. 4:431–435. 1993. View Article : Google Scholar : PubMed/NCBI
19	Levin RD and Gordon JH: Fluorodeoxyuridine with continuous leucovorin infusion. A phase II clinical trial in patients with metastatic colorectal cancer. Cancer. 72:2895–2901. 1993. View Article : Google Scholar : PubMed/NCBI
20	Myers CE, Young RC and Chabner BA: Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion. J Clin Invest. 56:1231–1238. 1975. View Article : Google Scholar : PubMed/NCBI
21	Howell SB, Ensminger WD, Krishan A and Frei E III: Thymidine rescue of high-dose methotrexate in humans. Cancer Res. 38:325–330. 1978.PubMed/NCBI
22	Francini G, Petrioli R, Lorenzini L, Mancini S, Armenio S, Tanzini G, Marsili S, Aquino A, Marzocca G, Civitelli S, et al: Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology. 106:899–906. 1994. View Article : Google Scholar : PubMed/NCBI
23	Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Nakayama G, Ohashi N, Koike M, Yamamura Y and Nakao A: Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: Correlation with drug sensitivity against 5-fluorouracil. Cancer Lett. 252:307–313. 2007. View Article : Google Scholar : PubMed/NCBI
24	Isshi K, Sakuyama T, Gen T, Nakamura Y, Kuroda T, Katuyama T and Maekawa Y: Predicting 5-FU sensitivity using human colorectal cancer specimens: Comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol. 7:335–342. 2002. View Article : Google Scholar : PubMed/NCBI
25	Santelli G and Valeriote F: In vivo potentiation of 5-fluorouracil cytotoxicity against AKR leukemia by purines, pyrimidines, and their nucleosides and deoxynucleosides. J Natl Cancer Inst. 64:69–72. 1980.PubMed/NCBI
26	Spiegelman S, Sawyer R, Nayak R, Ritzi E, Stolfi R and Martin D: Improving the anti-tumor activity of 5-fluorouracil by increasing its incorporation into RNA via metabolic modulation. Proc Natl Acad Sci USA. 77:pp. 4966–4970. 1980; View Article : Google Scholar : PubMed/NCBI
27	Hunsucker SA, Spychala J and Mitchell BS: Human cytosolic 5′-nucleotidase I: Characterization and role in nucleoside analog resistance. J Biol Chem. 276:10498–10504. 2001. View Article : Google Scholar : PubMed/NCBI